EXCLUSIVE: Fauci’s Agency Scrambled to Answer Questions on Changing Remdesivir Trial Endpoint: Emails

Click here to read the full article.

Dr. Anthony Fauci and top officials at the agency he heads scrambled in April 2020 to answer questions about altering the endpoint in a trial testing the antiviral drug called remdesivir, newly obtained emails show.

The endpoint was changed in the middle of the trial from measuring the effectiveness against death and various forms of hospitalization on day 15 to time to recovery through day 29.

Gilead Sciences, which makes the drug, announced the results of the trial in early April 29, 2020. Within hours, Fauci, the longtime head of the National Institute of Allergy and Infectious Diseases (NIAID), was trumpeting them to reporters at the White House.

The trial results proved that remdesivir “can block the virus” that causes COVID-19, said Fauci, who didn’t mention the change in endpoint.

Continue reading here.

Scroll down for comments and share your thoughts!

What do you think?

Leave a Reply

Your email address will not be published.

GIPHY App Key not set. Please check settings

All-girls California high school has students make 'pronoun buttons' at diversity festival

LIVE: Survivors Recount Atrocities of the Chinese Communist Party